» Articles » PMID: 35562878

Therapeutic Potential of Exosomes Derived from Adipose Tissue-Sourced Mesenchymal Stem Cells in the Treatment of Neural and Retinal Diseases

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2022 May 14
PMID 35562878
Authors
Affiliations
Soon will be listed here.
Abstract

Therapeutic agents that are able to prevent or attenuate inflammation and ischemia-induced injury of neural and retinal cells could be used for the treatment of neural and retinal diseases. Exosomes derived from adipose tissue-sourced mesenchymal stem cells (AT-MSC-Exos) are extracellular vesicles that contain neurotrophins, immunoregulatory and angio-modulatory factors secreted by their parental cells. AT-MSC-Exos are enriched with bioactive molecules (microRNAs (miRNAs), enzymes, cytokines, chemokines, immunoregulatory, trophic, and growth factors), that alleviate inflammation and promote the survival of injured cells in neural and retinal tissues. Due to the nano-sized dimension and bilayer lipid envelope, AT-MSC-Exos easily bypass blood-brain and blood-retinal barriers and deliver their cargo directly into the target cells. Accordingly, a large number of experimental studies demonstrated the beneficial effects of AT-MSC-Exos in the treatment of neural and retinal diseases. By delivering neurotrophins, AT-MSC-Exos prevent apoptosis of injured neurons and retinal cells and promote neuritogenesis. AT-MSC-Exos alleviate inflammation in the injured brain, spinal cord, and retinas by delivering immunoregulatory factors in immune cells, suppressing their inflammatory properties. AT-MSC-Exos may act as biological mediators that deliver pro-angiogenic miRNAs in endothelial cells, enabling re-vascularization of ischemic neural and retinal tissues. Herewith, we summarized current knowledge about molecular mechanisms which were responsible for the beneficial effects of AT-MSC-Exos in the treatment of neural and retinal diseases, emphasizing their therapeutic potential in neurology and ophthalmology.

Citing Articles

Future Directions in Diabetic Retinopathy Treatment: Stem Cell Therapy, Nanotechnology, and PPARα Modulation.

Kapa M, Koryciarz I, Kustosik N, Jurowski P, Pniakowska Z J Clin Med. 2025; 14(3).

PMID: 39941353 PMC: 11818668. DOI: 10.3390/jcm14030683.


Stem Cell-Derived Extracellular Vesicle-Mediated Therapeutic Signaling in Spinal Cord Injury.

Poongodi R, Hsu Y, Yang T, Huang Y, Yang K, Lin H Int J Mol Sci. 2025; 26(2).

PMID: 39859437 PMC: 11765593. DOI: 10.3390/ijms26020723.


Extracellular vesicles from mesenchymal stem cells improve neuroinflammation and neurotransmission in hippocampus and cognitive impairment in rats with mild liver damage and minimal hepatic encephalopathy.

Mincheva G, Moreno-Manzano V, Felipo V, Llansola M Stem Cell Res Ther. 2024; 15(1):472.

PMID: 39696620 PMC: 11656658. DOI: 10.1186/s13287-024-04076-6.


Exosomal Non-coding RNA Derived from Mesenchymal Stem Cells (MSCs) in Autoimmune Diseases Progression and Therapy; an Updated Review.

Farhan S, Jasim S, Bansal P, Kaur H, Abed Jawad M, Qasim M Cell Biochem Biophys. 2024; 82(4):3091-3108.

PMID: 39225902 DOI: 10.1007/s12013-024-01432-4.


Advances in Extracellular-Vesicles-Based Diagnostic and Therapeutic Approaches for Ocular Diseases.

Su Y, Chen M, Xu W, Gu P, Fan X ACS Nano. 2024; 18(34):22793-22828.

PMID: 39141830 PMC: 11363148. DOI: 10.1021/acsnano.4c08486.


References
1.
Jellinger K . Neuropathological assessment of the Alzheimer spectrum. J Neural Transm (Vienna). 2020; 127(9):1229-1256. DOI: 10.1007/s00702-020-02232-9. View

2.
Rahman M, Akhtar N, Jamil H, Banik R, Asaduzzaman S . TGF-β/BMP signaling and other molecular events: regulation of osteoblastogenesis and bone formation. Bone Res. 2015; 3:15005. PMC: 4472151. DOI: 10.1038/boneres.2015.5. View

3.
Shang Q, Chu Y, Li Y, Han Y, Yu D, Liu R . Adipose-derived mesenchymal stromal cells promote corneal wound healing by accelerating the clearance of neutrophils in cornea. Cell Death Dis. 2020; 11(8):707. PMC: 7450061. DOI: 10.1038/s41419-020-02914-y. View

4.
Oh J, Lee R . Mesenchymal stromal cells for the treatment of ocular autoimmune diseases. Prog Retin Eye Res. 2021; 85:100967. PMC: 8922475. DOI: 10.1016/j.preteyeres.2021.100967. View

5.
Harrell C, Djonov V, Volarevic V . The Cross-Talk between Mesenchymal Stem Cells and Immune Cells in Tissue Repair and Regeneration. Int J Mol Sci. 2021; 22(5). PMC: 7957490. DOI: 10.3390/ijms22052472. View